Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04096443 · ClinicalTrials.gov registry record · Early Phase 1
Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis
A Early Phase 1 study of Multiple Sclerosis, sponsored by Griffin Hospital.
- Active
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT04096443: Active Early Phase 1 study of Multiple Sclerosis, sponsored by Griffin Hospital.
NCT04096443 is a Early Phase 1 study of Multiple Sclerosis that is active but no longer recruiting, run by Griffin Hospital. The registered enrollment target is 9 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04096443, a Early Phase 1 study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Griffin Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this pilot study is to determine whether fecal microbial transplant (FMT) has the potential to be an effective, safe and tolerable therapy for the treatment of multiple sclerosis (MS). The investigators plan to gather preliminary data in a small cohort of 10 to 15 adults with MS.
Primary Outcome
Evidence of engraftment as measured by 16s rRNA microbiome sequencing
Conditions Studied
Interventions
- BIOLOGICAL Fecal microbial transplant (FMT)
Study Locations (1)
Connecticut
- Griffin Hospital - Derby
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-10-28 |
| Est. Completion | 2024-12-30 |
| Phase | Early Phase 1 |
What the registry record for NCT04096443 still lists
NCT04096443 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Fecal microbial transplant (FMT) is the first listed.
NCT04096443 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04096443 about?
NCT04096443 is a clinical study titled "Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis". The goal of this pilot study is to determine whether fecal microbial transplant (FMT) has the potential to be an effective, safe and tolerable therapy for the treatment of multiple sclerosis (MS). The investigators plan to gather preliminary data in a small cohort of 10 to 15 adults with MS.
What is the current status of trial NCT04096443?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2019-10-28. Estimated completion is 2024-12-30.
What conditions does trial NCT04096443 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT04096443?
The interventions under investigation include: Fecal microbial transplant (FMT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04096443?
This trial is sponsored by Griffin Hospital, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04096443 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04096443's enrollment target sits among peer trials
9 308th of 315 higher than 8 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Entire-body PET Scans for Multiple Sclerosis
RECRUITING · Early Phase 1
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
Assessment of Synaptic Density in MS
RECRUITING · Early Phase 1
-
Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis
ACTIVE NOT RECRUITING · Early Phase 1
-
Novel Imaging Markers in SPMS
COMPLETED · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI